ZYBERNO
Stock Report
Updated Sep 1, 2026

REGEN BIOPHARMA, INC. (RGBP)

Healthcare • OTC

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
16.0/100
POOR BUSINESS
REGEN BIOPHARMA, INC. (RGBP) scores 16/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-339.8%)
Return on Capital (Capital Efficiency):CRITICAL (-209.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

REGEN BIOPHARMA, INC. (RGBP) stock report — Zyberno Score 16/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$61.56K

Valuation Multiples (2)

P/S Ratio:0.26x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$2.07M
B. Profitability Assessment

Margin Analysis (3)

Operating Margin Ttm:-339.8%
Net Margin Ttm:-501.4%
Ebitda Margin:-339.8%

TTM Performance (2)

Operating Margin Ttm:-339.8%
Net Margin Ttm:-501.4%

Yield Metrics (2)

Earnings Yield:-$50.00K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:100.0%
Latest Earnings Filed:2026-08-17

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):24.6%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.05x
Quick Ratio:0.05x
Cash Ratio:0.00x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1.99x
Times Interest Earned:-1.99

Capital Structure (4)

Working Capital:-5,878,206.00
Cash And Cash Equivalents:239.00
Long Term Debt:$0.00
Net Debt:$2.01M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $236.56K
Linear Growth: 24.6%
📊 Click to view full RGBP Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$803.86K

Bottom Line Performance (3)

-$1.19M
Income Before Tax:-$1.19M
Ebitda Ttm:-803,862.00

Operating Expenses (5)

Operating Expenses:1,040,422.00
R And D Expense:191,441.00
Sga Expense:295,622.00
Income Tax Expense:$0.00
Interest Expense:170,268.00

Expense Ratios (3)

R And D To Revenue Percentage:324.1%
Sga To Revenue Percentage:500.5%
Ebitda Margin:-339.8%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$287.59K
Current Assets:$287.59K
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:6,165,793.00
Current Liabilities:6,165,793.00
Long Term Debt:$0.00
Short Term Debt:$2.01M

Equity & Capital (3)

Equity:-$5.88M
Retained Earnings:-$22.31M
Common Stock:5,800,000,000.00

Working Capital Items (3)

Accounts Receivable:287,147.00
Inventory:0.00
Accounts Payable:2,007,987.00

Special Items (2)

Contract Liabilities:1,243,691.00
Stock Based Compensation:13,048.00
C. Cash Flow Analysis

Operating Activities (2)

-$515.15K$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$132.96K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:191,800.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.05
Eps diluted TTM: -$0.05
Linear Growth: -10.8%
📊 Click to view full RGBP EPS analysis & methodology →
Earnings Per Share Ttm:-$0.00

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.00

Book Value & Capital (2)

Book Value Per Share:-$0.01
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.89x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:0.82x
Days Sales Outstanding Ttm:443.05

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:3,098.21
Cash Conversion Cycle:-3,654.16
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):24.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:RGBP
Company Name:REGEN BIOPHARMA, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:615.56M
Shares Outstanding Basic:615.56M
Shares Outstanding Diluted:615.56M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 23:41:05 UTC
Data Timestamp:2026-08-22T21:18:27.280847
Scroll to Top